Symbiotec Pharmalab

· NSE upcoming

Opens in 5 days · 24 Aug 2026

₹220

GMP* · 19 Aug, 06:20 pm

Price Band

—

Issue Size

—

1 lot at upper band

—

Lot Size

Open

24 Aug 2026

27 Aug 2026

Allotment

—

Listing

01 Sept 2026

Scheduled dates

Open

24 Aug 2026
Close

27 Aug 2026
Listing

01 Sept 2026

GMP Trend*

Daily grey market premium (₹). Unofficial.

Only one GMP reading available — trend needs at least two.

Subscription (times)

Latest per-category subscription.

Bidding hasn't opened yet — subscription starts once the issue opens.

About Symbiotec Pharmalab

Symbiotec Pharmalab Limited is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms: organic chemistry, biotechnology and complex injectables. The company holds a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs) in volume terms, with a global volume market share of 38.2% in corticosteroid and 23.8% in steroidal-hormone APIs. The company operates as a contract development and manufacturing organisation (CDMO) for specialty pharmaceutical and nutraceutical companies globally, offering products and services across the three platforms.

www.symbiotec.com ↗

Strengths

Global leadership in corticosteroid and steroidal-hormone APIs

The company holds a global leadership position with 38.2% market share in corticosteroid and 23.8% in steroidal-hormone APIs in Fiscal 2026, being the only company globally with presence across top 10 APIs in this category.
Long-standing relationships with domestic and global customer base

The company serves over 200 customers across 40+ countries with average relationship tenure of more than 10 years with top customers, demonstrating strong customer stickiness and retention capabilities.
Fully-invested, multi-scale, vertically integrated manufacturing platform with sustainable practices and clean regulatory track record

The company operates with 584.67 MT chemical synthesis capacity, 700 KL fermentation capacity, and 20 million vials complex injectables capacity, having completed 108+ inspections without critical observations from global regulators.
Continuous investment in R&D, with leading technological capabilities among Indian peers

The company invested 3.42% of revenue in R&D in Fiscal 2026 with 156 scientists across three platforms, enabling manufacturing of APIs with up to 400 synthesis steps validated under cGMP.
Ability to leverage science and existing competencies to increase total addressable market and deepen intellectual property-driven offerings

The company successfully expanded into classical fermentation APIs, CDMO services with take-or-pay contracts, and complex injectables commanding 20-50% price premium over conventional injectables.
Robust financials with strong gross margins, high capital efficiency and cash conversion

The company achieved revenue CAGR of 10.16% (Fiscal 2024-2026), gross margins of 63.70% in Fiscal 2026, and maintained CARE A+ credit rating across three consecutive fiscals.
Seasoned leadership team supported by strong pool of experienced management and marquee investors

The company is led by experienced management with 30+ years pharmaceutical experience, backed by marquee investors including Rosewood Investments, Motilal Oswal Alternates, and historically Actis and Franklin Templeton.

Risk Factors

High Revenue Concentration in APIs

The company derives almost all revenue from API sales (96.07%, 99.10%, and 100.00% in Fiscals 2026, 2025, and 2024 respectively), with top five APIs constituting 62.27%, 63.16%, and 60.37% of revenue. Any reduction in API demand or production disruption could severely impact business operations and financial performance.
Regulatory Compliance and Manufacturing Quality Risks

The company's manufacturing facilities are subject to periodic inspections by regulatory authorities and customers. Manufacturing or quality control failures may result in regulatory action, reputation damage, and business disruption. Recent US FDA inspections resulted in Form 483 observations requiring responses.
Significant Export Revenue Exposure

The company generates 67.04%, 55.19%, and 59.97% of revenue from external customers outside India in Fiscals 2026, 2025, and 2024 respectively. The company faces risks from foreign exchange fluctuations, geopolitical tensions, trade restrictions, and varying regulatory requirements across multiple jurisdictions.
Customer Concentration Risk

The company derives substantial revenue from key customers, with top ten customers accounting for 57.59%, 55.90%, and 61.65% of product sales in Fiscals 2026, 2025, and 2024 respectively. Loss of key customers or order reductions could significantly impact financial performance, especially given the lack of long-term contractual arrangements.
Geographic Concentration of Manufacturing Operations

All manufacturing facilities and R&D centers are located in Madhya Pradesh, India, creating vulnerability to regional disruptions. Any adverse developments affecting the state or surrounding regions, including natural disasters, political instability, or infrastructure failures, could severely impact business operations.
Supplier Dependency and Raw Material Supply Chain Risks

The company depends on key suppliers for raw materials, with top ten suppliers accounting for 25.50%, 18.41%, and 50.33% of total expenses in Fiscals 2026, 2025, and 2024 respectively. The company procures significant raw materials from China (23.88% of total expenses in Fiscal 2026), exposing it to supply chain disruptions and geopolitical risks.
Intense Market Competition

The company operates in highly competitive API manufacturing and CDMO markets, facing competition from established pharmaceutical companies with potentially greater resources. Competitors may have lower production costs, better market positioning, and superior technical capabilities, requiring continuous investment in R&D and manufacturing capabilities to remain competitive.
Working Capital and Financial Leverage Risks

The company requires substantial working capital with current ratio declining from 1.45 to 0.92 between Fiscal 2024 and 2026. Total borrowings amount to ₹3,879.14 million as of March 31, 2026, with financing agreements containing restrictive covenants that could limit operational flexibility and require additional capital for growth.

Objects of the Issue

Prepayment and/or repayment of outstanding borrowings
The company proposes to utilize the net proceeds towards prepayment and/or repayment, in full or in part, of certain outstanding borrowings to reduce overall indebtedness, debt servicing costs, and maintain favorable debt-equity ratio.

112.50 crores
General corporate purposes
The company proposes to utilize the balance net proceeds for general corporate purposes including meeting ongoing contingencies, business requirements, funding growth opportunities, and strategic initiatives as approved by the Board.

Financial Snapshot

Annual values as reported in the offer document.

Year end	Revenue	Rev. growth	Profit	Profit growth	Assets	Equity	Operating cash flow
31/03/2026	872.26	+15.4%	109.90	+13.5%	1780.79	1149.59	174.59
31/03/2025	755.98	+4.5%	96.79	-3.3%	1579.65	814.71	47.26
31/03/2024	723.33	—	100.06	—	1294.79	714.84	187.50

Units: crores

Issue Details

Face Value: ₹2
P/E: 55.44
ROCE: 11.80%
CIN: U24232MP2002PLC015293
Registrar: MUFG Intime India Pvt.Ltd.
Lead Managers: JM Financial Ltd.
Registered Office: 385/2, Pigdamber, Rau, Mhow, Indore – 453 331, Madhya Pradesh, India

RHP ↗DRHP ↗

Management

Anil SatwaniMD

Rohit MantriDirector

Sunita KishnaniDirector

Pratik PatelDirector

Pramod KasatDirector

* Grey Market Premium is unofficial, indicative data from unregulated grey-market dealers. It is not published by NSE, BSE, SEBI or the issuer, and is not a forecast of the listing price.